Non-hormonal treatment for menopausal hot flashes begins clinical trials
![](/46/pdcnewsitem/08/22/92/white-desk-fan-on-white-table-3675622%20(1).jpg)
The study will evaluate the efficacy of SJX-653 in reducing the frequency and severity of VMS due to menopause, as well as improving measures of sleep and quality of life.
Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, has announced the initiation of a Phase II trial of SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist in clinical development as a non-hormonal once-daily (QD) treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.
“Though millions of women suffer from hot flashes, current therapies for VMS often leave women searching for better alternatives,” said Ruth Thieroff-Ekerdt, Chief Medical Officer at Sojournix. “Many women choose to avoid hormone therapy, and current non-hormonal options often provide unsatisfactory symptom relief. Women and their doctors need new non-hormonal treatment options with meaningful clinical efficacy, and SJX-653 aims to address this important unmet medical need.”
The Phase II clinical trial is a 12-week, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of SJX-653 in reducing the frequency and severity of vasomotor symptoms (VMS) due to menopause, as well as improving measures of sleep and quality of life. Following a screening period, participants will be randomized to receive one of two doses of SJX-653 or placebo administered orally once-daily (QD) each morning. The study is anticipated to enroll approximately 130 postmenopausal women who are experiencing moderate to severe VMS.
“The progression of SJX-653 into this Phase II clinical trial represents a significant milestone in bringing SJX-653 to patients,” said Daniel Grau, CEO and President of Sojournix. “NK3 antagonism is a well-validated mechanism of action, and we believe SJX-653 has the potential to become a new standard of care medicine for menopausal women seeking non-hormonal treatment options for VMS.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance